StockData
Dermata Therapeutics, Inc. logo

Dermata Therapeutics, Inc. (DRMA) company profile

DRMANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$0.62−0.04 (-6.01%)

Close on Nov 13, 2026Market cap $2.50MP/E –Yield –

About Dermata Therapeutics

Pharmaceutical Preparations, SIC 2834

Dermata Therapeutics, Inc. is a scientific skincare company focused on developing and commercializing treatments for common and underserved dermatological conditions, such as acne. The company is shifting its strategic focus from prescription pharmaceuticals toward science-backed, direct-to-consumer and professional business-to-business skincare lines, branded as Tome. Its planned product portfolio includes foundational topical treatments and over-the-counter acne systems utilizing a purified freshwater sponge powder known as Spongilla lacustris, or Bioneedle, combined with active ingredients like salicylic acid. Beyond topical acne solutions, the company explores applications for its microstructure technology to facilitate intradermal delivery of aesthetic treatments.

The company's primary target market includes consumers seeking over-the-counter skin wellness products as well as dermatologists and aesthetic healthcare professionals. Dermata operates from its principal executive offices located in San Diego, California. The text does not report retail store locations or international business figures.

Summary of the business section of Dermata Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Dermata Therapeutics, Inc.
Headquarters
San Diego, CA
Address
3525 Del Mar Heights Rd., #322 92130
Phone
(858) 223-0882
Employees
9, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
CBIZ CPAs P.C, San Diego, California

Stock & identifiers

Ticker
DRMA
Exchange
Nasdaq
IPO date
Aug 16, 2021
Shares outstanding
4M, Aug 10, 2026
Public float
$3.10M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-10 reverse, Aug 1, 2025; 1-for-15 reverse, May 16, 2024; 1-for-16 reverse, Mar 14, 2023
SEC CIK
1853816
CUSIP
249845108
ISIN
US2498451085
FIGI
BBG011DJT0X2
Share class FIGI
BBG011DJT0Y1
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Gerald T. ProehlPRESIDENT, CHAIRMAN, CEO, Director372,615
Hoose Kyri K. VanSVP, CFO232,463
Munera Maria E. Bedoya-ToroSVP, Regulatory Affairs1,046
Christopher J. NardoSenior VP, CDO27,560
Kathleen D. ScottDirector1
Mary FisherDirector196,946
Andrew Seth SandlerDirector24,184
David F. HaleDirector81,469
Steven J. MentoDirector–
Wendell WierengaDirector62,398
Brittany BradrickDirector23,443

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsTotalvs. prior year
Gerald T. Proehl
President and Chief Executive Officer
$280.00K$140.00K$52.52K$472.52K+2%
Kyri K. Van Hoose
Senior Vice President, Chief Financial Officer
$346.57K$138.63K$23.34K$508.54K+9%
Christopher J. Nardo, Ph.D.
Senior Vice President, Chief Development Officer
$366.98K$146.79K$23.34K$537.11K+9%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 16, 2021
Offer price
$7.00
Securities offered
2,571,428
Gross proceeds
$18.00M
Exchange
Nasdaq
First trading day
Aug 13, 2021
First-day close
$5.19-25.9%
Lock-up ends (est.)
Feb 9, 2022

“Per Unit Total Initial public offering price $ 7.00 $ 17,999,996 Underwriting discounts and commissions (1) $ 0.56 $ 1,440,000 Proceeds to us, before expenses $ 6.44 $ 16,559,996 (1) Does not include the reimbursement of certain expenses of the underwriters.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of the date of this report, we have nine full-time employees, with four employees working in the selling, general and administrative department, two engaged in non-clinical and clinical development, two working in the chemistry, manufacturing, and controls department, and one employee working in the regulatory affairs and quality control department.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?